XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

Core Insights - XORTX Therapeutics Inc. has entered into a binding term sheet to acquire a Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems Limited, which includes the novel compound VB4-P5 and associated intellectual property [1][2] - The VB4-P5 program is at the pre-IND stage and aims to address both rare and common forms of kidney disease, which have significant unmet medical needs [1][2] Company Overview - XORTX is focused on developing innovative therapies for gout and progressive kidney disease, with a mission to provide new treatment options for patients suffering from rare renal disorders [2][8] - The company has three clinically advanced products: XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury related to respiratory virus infections [8] Acquisition Details - The acquisition consideration for Vectus is USD $3.0 million, payable in common shares or equivalents at a deemed issue price of USD $0.86 per Security [2][3] - The closing of the acquisition is expected to occur within 90 days, subject to typical conditions including regulatory approvals [3] Kidney Disease Context - Chronic kidney disease (CKD) affects approximately 14% of adults globally, translating to around 35–37 million individuals in the United States [4] - Kidney fibrosis is a key factor in CKD progression, leading to significant morbidity and mortality, with current treatments primarily focusing on blood pressure control and dietary changes [5] VB4-P5 Program Insights - Early preclinical data suggest that VB4-P5 has the potential to inhibit and possibly reverse kidney fibrosis, with patent protection covering over 30 global jurisdictions [6]